Druml Christiane
Ethics Committee of the Medical University of Vienna and The Vienna General Hospital, Vienna, Austria.
Curr Opin Crit Care. 2004 Dec;10(6):570-3. doi: 10.1097/01.ccx.0000144765.73540.89.
The new European legislation on good clinical practice in the conduct of clinical trials on drugs has raised serious concern that potentially lifesaving studies cannot be carried out in critically ill patients in Europe anymore after May 2004. The requirement of nominating a legal representative for obtaining informed consent before inclusion will deprive current and future patients of participation in research. The new legislation does not differentiate between patients who are incompetent because of a psychiatric illness or dementia and patients who are incapacitated owing to an emergency situation. All those patients may be enrolled in a clinical trial only after informed consent has been granted by a legal representative.
Recent publications regarding the new European legislation manifest an outcry by intensive care specialists, emergency medicine specialists, traumatologists, and specialists of other related disciplines concerned about the proposed active withholding of potentially beneficial therapies for this very unfortunate group of patients. Many authors, although acknowledging the ethical principle of autonomy, express that in the field of emergency medicine not all criteria of autonomy may be met. The Declaration of Helsinki requires that even the best prophylactic, diagnostic, and therapeutic methods must continuously be challenged through research. There is agreement among the authors that critically ill patients should not be deprived from the benefits of research.
Many groundbreaking therapies will not be scientifically evaluated anymore, and thus beneficial treatments in fatal diseases will be prevented. The European legislation is asked to adapt the Directive to promote research in critically ill patients.
欧洲关于药物临床试验良好临床实践的新立法引发了严重担忧,即2004年5月之后,在欧洲可能无法再对重症患者开展具有潜在救生作用的研究。在纳入患者之前要求指定法定代理人以获取知情同意,这将使当前和未来的患者失去参与研究的机会。新立法没有区分因精神疾病或痴呆而无行为能力的患者和因紧急情况而丧失行为能力的患者。所有这些患者只有在法定代理人给予知情同意后才可纳入临床试验。
近期有关欧洲新立法的出版物表明,重症监护专家、急诊医学专家、创伤学家以及其他相关学科的专家强烈抗议对这一非常不幸的患者群体主动停止使用潜在有益治疗方法的提议。许多作者虽然承认自主原则,但表示在急诊医学领域可能无法满足自主的所有标准。《赫尔辛基宣言》要求,即使是最佳的预防、诊断和治疗方法也必须通过研究不断受到挑战。作者们一致认为,不应剥夺重症患者从研究中获益的机会。
许多开创性疗法将不再进行科学评估,从而会阻碍对致命疾病的有益治疗。要求欧洲立法调整指令,以促进对重症患者的研究。